Chemomab Therapeutics (CMMB) Income from Continuing Operations (2017 - 2026)
Chemomab Therapeutics (CMMB) posted Income from Continuing Operations of $2.17 million for Q2 2026, up 5.3% from $2.06 million a year earlier and up 22.1% from the prior quarter.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Income from Continuing Operations (2017 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Income from Continuing Operations at Chemomab Therapeutics was $7.55 million, down 36.1% year-over-year; for FY2025, it was $9 million, down 35.5% from FY2024.
- Annual Income from Continuing Operations has declined for three consecutive years, with a four-year compound annual growth rate of -7.9% (FY2021 to FY2025).
- In prior years, Chemomab Therapeutics' Income from Continuing Operations was $13.95 million in FY2024 (-42.4%), $24.22 million in FY2023 (-15.6%), $28.71 million in FY2022 (+130.1%) and $12.48 million in FY2021.
- The Q2 2026 figure stands as the highest quarterly Income from Continuing Operations since Q1 2025.
- On a year-over-year basis, Income from Continuing Operations increased in 1 of the last eight quarters, with an average decline of 27.0%.
- The strongest year-over-year quarter for Income from Continuing Operations in the past five years was Q2 2023, with growth of 8.6%; the weakest was Q4 2023, with a decline of 58.6%.
- According to Business Quant data, Income from Continuing Operations for the three prior quarters was $1.77 million (Q1 2026), $1.87 million (Q4 2025) and $1.74 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Chemomab Therapeutics | 8.56 Mn | 8.56 Mn | - | 2.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.17 Mn |
| Mar 31, 2026 | 1.77 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 2.06 Mn |
| Mar 31, 2025 | 3.32 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 4.19 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | 8.25 Mn |
| Sep 30, 2022 | 8.08 Mn |
| Jun 30, 2022 | 7.28 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | 19.92 Mn |
| Sep 30, 2021 | -2.97 Mn |
API Access
Chemomab Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=CMMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "CMMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=CMMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();